The effects of D 9-tetrahydrocannabinol and cannabidiol alone and in combination on damage , inflammation and in vitro motility disturbances in rat colitisbph

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats.

  2009cited by this paper
• A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti‐inflammatory effects in lipopolysaccharide‐induced sepsis in mice

  2009cited by this paper
• Guide to Receptors and Channels (GRAC), 4th edition

  2009cited by this paper
• Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis

  2009influential reference
• Synthetic and plant‐derived cannabinoid receptor antagonists show hypophagic properties in fasted and non‐fasted mice

  2009cited by this paper
• Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation

  2008cited by this paper
• Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase

  2008cited by this paper
• Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2

  2008cited by this paper
• Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice

  2008cited by this paper
• Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.

  2008cited by this paper
• Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug.

  2008cited by this paper
• Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

  2008cited by this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

  2008cited by this paper
• The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT).

  2008cited by this paper
• (919): Cannabis use by patients with inflammatory bowel disease

  2007cited by this paper
• Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis.

  2007cited by this paper
• Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor‐independent myeloperoxidase‐inhibiting mechanism

  2007cited by this paper
• [Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease].

  2007cited by this paper
• Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression.

  2007cited by this paper
• Inflammatory bowel disease: clinical aspects and established and evolving therapies

  2007influential reference
• Cannabinoids, immune system and cytokine network.

  2006cited by this paper
• Cannabidiol lowers incidence of diabetes in non-obese diabetic mice

  2006cited by this paper
• A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.

  2006cited by this paper
• Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium.

  2006cited by this paper
• Role of TNF‐α in muscularis inflammation and motility disorder in a TNBS‐induced colitis model: clues from TNF‐α‐deficient mice

  2006cited by this paper
• Plant cannabinoids: a neglected pharmacological treasure trove

  2005cited by this paper
• Review article: endocannabinoids and their receptors in the enteric nervous system

  2005cited by this paper
• Persistent and selective effects of inflammation on smooth muscle cell contractility in rat colitis

  2004cited by this paper
• The endogenous cannabinoid system protects against colonic inflammation.

  2004cited by this paper
• Cannabinoids and multiple sclerosis.

  2002cited by this paper
• Cannabidiol: An Overview of Some Pharmacological Aspects

  2002cited by this paper
• Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes.

  2001cited by this paper
• Morphological and Functional Alterations of the Myenteric Plexus in Rats with TNBS-Induced Colitis

  2001cited by this paper
• The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.

  2000influential reference
• Neuromuscular Dysfunction in the Jejunum and Colon of Human Leukocyte Antigen B 27 Transgenic Rats 1

  2000cited by this paper
• The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease

  1999cited by this paper
• Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells.

  1998cited by this paper
• The mechanism of altered neural function in a rat model of acute colitis.

  1997cited by this paper
• The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders.

  1996cited by this paper
• Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs.

  1995cited by this paper
• Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro.

  1991cited by this paper
• Assessment of leukocyte involvement during ischemia and reperfusion of intestine.

  1990cited by this paper
• Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat.

  1990cited by this paper
• Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.

  1989cited by this paper
• Hapten-induced model of chronic inflammation and ulceration in the rat colon.

  1989cited by this paper
• The effect of anti‐inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat

  1988cited by this paper
• Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats.

  1984cited by this paper
• Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

  1984cited by this paper
• Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.

  1982cited by this paper
• Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.

  1974cited by this paper
• Interaction of Δ9‐tetrahydrocannabinol and cannabidiol on intestinal motility in mice

  1974cited by this paper
• Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat.

  1974cited by this paper
• Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol.

  1973cited by this paper

• The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (PTSD): A Systematic Review

  2019cites this paper